

Product Datasheet

TAK788

Catalog No. **BP-02352** · CAS **1847461-43-1** · Form **free base** · Physical state **solid** · Color **Off-white to light yellow** · Version **1.0** · Revision **2026-09-10**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target EGFR	Research area Cancer
-----------------------	--------------------------------

Molecular formula **C₃₂H₃₉N₇O₄**

Molecular weight **585.6966**

STRUCTURE



DESCRIPTION

Mobocertinib (TAK-788; AP32788) is an investigational TKI with potent, selective preclinical activity against activating EGFR and HER2 mutations, including exon 20 insertions. TAK-788 exhibits antitumor activity in pts with EGFR exon 20 insertions with an AE profile consistent with other EGFR TKIs.

BIOLOGICAL ACTIVITY

Mobocertinib (TAK-788) is an investigational TKI with potent, selective preclinical activity against activating EGFR and HER2 mutations, including exon 20 insertions. Mobocertinib (TAK-788) inhibits all 14 mutant variants of EGFR (IC₅₀s=2.4-22 nM), and all 6 mutant variants of HER2 (IC₅₀s=2.4-26 nM), more potently than it inhibited WT EGFR (IC₅₀=35 nM). Daily oral dosing of Mobocertinib in mice implanted with a patient-derived tumor containing an EGFR exon 20 activating insertion induced regression of tumors at doses that were well tolerated (30-100 mg/kg).

SOLUBILITY

Soluble in DMSO

REFERENCES

- [1]. Gonzalez F, et al. Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. Cancer Discov. 2021 Jul;11(7):1672-1687.
- [2]. Han H, et al. Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib. Cancer Res. 2021 Oct 15;81(20):5311-5324.